Investing analyses

# HNGE — Q4 FY25 Earnings Review (Atlas)

> Date: 2026-02-23 (updated; prior version 2026-02-21)
> Quarter: Q4 FY25 (Oct–Dec 2025)
> Market cap: ~$3.3B | EV/TTM Rev: ~5.6x | Revenue growth: +45.5% YoY (Q4), +51% FY25 | Rule of 40: 81

---

## Verdict

HNGE delivered an exceptional Q4 and FY25. Revenue beat by $13.9M (8.7%), Non-GAAP EPS beat consensus by 250% ($0.49 vs $0.14), and the company achieved first GAAP operating profitability two quarters ahead of expectations. Rule of 40 of 81 is elite-tier. The stock trades at 5.6x TTM revenue — roughly half the multiple justified by the growth/margin profile. FY26 guidance of 25% growth is management's standard conservative sandbag; the Q1 FY26 guide alone ($171–173M, +39% YoY) makes the 25% full-year guide mathematically implausible without dramatic H2 deceleration that the leading indicators do not support. **Conviction: 4/5.** Primary risk is real growth deceleration as the ASO market matures and non-ASO economics remain unproven at scale.

---

## Qualification Gate

| Criterion | Threshold | Actual | Status |
|-----------|-----------|--------|--------|
| Revenue YoY growth | >30% (>40% preferred) | +45.5% Q4, +51% FY25 | **PASS** |
| Gross margin | >60% (>70% preferred) | 85% Non-GAAP | **PASS** |
| Revenue per quarter | >$50M | $170.7M | **PASS** |
| Data availability | 4+ quarters | 12 quarters (pre-IPO estimated) | **PASS** |
| Share dilution | <10% annual | <3% SBC dilution | **PASS** |
| GAAP profitability trajectory | Improving or positive | First GAAP op profit Q4 FY25 | **PASS** |

All six criteria pass. Pre-IPO quarters (FY23) estimated from S-1 disclosures. Post-IPO data (Q2–Q4 FY25) is fully audited.

---

## Six-Factor Score

| Factor | Rating | Detail |
|--------|--------|--------|
| Growth | **Strong** | +45.5% Q4 YoY; +51% FY25 full year. Absolute revenue $170.7M/Q. |
| Trajectory | **Decelerating (managed)** | 55% → 53% → 45.5% over last 3 quarters. Base-effect driven, not demand-driven. Client adds

*…truncated*

# HNGE — Stock Analysis (March 2026)
**Date:** 2026-03-27 | **Position:** Long, 7.4% | **By:** wsm007

---

## Verdict

Three S-curves stacking, 85% gross margins, Rule of 40 = 82, and a 25% FY26 guide that is mathematically impossible unless the business falls off a cliff in H2. It won't. At 5x run-rate P/S with $180M in annual FCF and zero debt, this is the cheapest quality compounder I own. Stock's up 40% since my Feb analysis — still cheap. **Thesis intact. Hold 7.4%. Add on Q1 beat.**

---

## The Structural Story

Before I touch a single number, the framing matters. HNGE is not a single-product company growing 50% that will decelerate to 20% and stall. It's a platform with **three growth curves at different maturities:**

1. **Core employer digital MSK** (mature growth): 2,830 clients, 53% of Fortune 100, 97% retention. Growing 25-30% organically. The beachhead.
2. **Engagement-based pricing + yield expansion** (growth phase): 50% of lives on EBP, yield 3.4% → 3.9% YoY. NDR >110%. This is the "expand" in land-and-expand — same clients, more revenue per life.
3. **Non-ASO channels** (embryonic): Medicare Advantage, FEP, fully-insured = 2.6M lives, +130% YoY. New TAM that's uncorrelated with employer ASO saturation.

And two more behind those:
4. **HingeSelect** (pre-revenue): Hybrid virtual+in-person network. "Not assuming really any revenue" in FY26. CEO: "1 of our most enduring competitive advantages." 2027+ contributor.
5. **Robin AI** (structural enabler): 47% more members served with flat care team costs. 28% reduction in async session time QoQ. This isn't a product — it's the margin expansion engine that funds everything else.

CEO Perez: "We didn't come this far automating physical therapy to stop at physical therapy." That's a sixth growth vector being telegraphed. This is a management team building a platform, not milking a product.

→ **When multiple growth vectors stack at different maturities, the single most common analytical error is modeling the 

*…truncated*

# HNGE — Hinge Health: Stock Analysis
**Philip A. Fisher | April 15, 2026**
**Market Cap:** ~$3.45B | **Share Price:** ~$39 | **IPO Price:** $32 (May 2025)

---

## What This Company Is

Hinge Health is a digital musculoskeletal care platform that serves self-insured employers, health plans, and — increasingly — public sector organizations. The company delivers physical therapy via a software application augmented by AI-driven care coaching, a proprietary wearable device (Enso), and, as of late 2025, an in-person provider referral network (HingeSelect). It generates revenue primarily through employer benefit contracts priced on an engagement basis.

The reason I find this business interesting — and the reason it qualifies for detailed examination under my framework — is that it sits at the intersection of three powerful forces: employer healthcare cost pressure, AI-enabled service delivery, and clinical evidence as a competitive moat. Companies that operate at such intersections, when managed by people of ability, tend to produce remarkable long-term returns.

---

## Scuttlebutt Findings

I begin, as always, with the mosaic of intelligence from those who interact with Hinge Health directly — customers, employees, competitors, partners, and industry observers. The financial statements will tell us what has happened; scuttlebutt illuminates what is happening and what is likely to happen.

### Customer Intelligence

The customer picture is bifurcated in a way I find revealing.

**The enterprise buyer loves this product.** Fifty-three percent of Fortune 100 companies and forty-five percent of the Fortune 500 have contracted with Hinge. Client retention stands at 97%, and net dollar retention exceeds 110%. Three of the five largest national health plans by self-insured lives now offer Hinge to their own employees — two won in 2025. A 200,000-life enterprise customer was converted from a competitor in Q4. The head-to-head competitive win rate is at an all-time high. Thes

*…truncated*

# HNGE — Hinge Health | Earnings Review Q4 FY25
**GauchoRico | 2026-02-22**

---

## Headline

Holy smokes!! Hinge Health delivered one of the cleanest post-IPO earnings reports I've seen in years. Q4 revenue of $170.7m beat guidance by $14.7m (+9.4%) — the third consecutive $12-14m beat. Gross margins hit 85%. Op margins expanded to 28%. FCF margin reached 36%. Rule of 40 came in at 82. This is a company that went from -$36.6m operating income in Q1 FY23 to $47.8m operating income in Q4 FY25, with 85% gross margins and a genuine AI operating leverage story. The deceleration from 51% to 46% matters — I'll address it — but the underlying business here is exceptional.

---

## Financial Table (12 Quarters)

| | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
| | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue ($m) | 60.0 | 69.4 | 78.4 | 84.9 | 87.5 | 93.8 | 92.4 | 116.7 | 126.9 | 139.1 | 154.2 | 170.7 |
| YoY % | — | — | — | — | 46% | 35% | 18% | 37% | 45% | 48% | 67% | 46% |
| QoQ % | — | 16% | 13% | 8% | 3% | 7% | -1% | 26% | 9% | 10% | 11% | 11% |
| GM [Non-GAAP] % | 62% | 64% | 67% | 68% | 71% | 73% | 74% | 76% | 80% | 83% | 85% | 85% |
| OpM [Non-GAAP] % | -61% | -49% | -37% | -24% | -18% | -12% | -9% | 3% | 9% | 17% | 22% | 28% |
| FCF ($m) | — | — | — | — | — | — | 25.0 | 20.2 | 27.9 | 37.0 | 53.1 | 61.5 |
| FCF Margin % | — | — | — | — | — | — | 27% | 17% | 22% | 27% | 34% | 36% |
| Non-GAAP EPS | — | — | — | — | — | — | — | $0.40 | $0.28 | $0.32 | $0.40 | $0.49 |

---

## Six-Factor Framework

### 1. Revenue Growth (>40% to qualify)
**PASS — but watching the trajectory**

Q4 FY25: 46% YoY. FY25 full year: 51% YoY. Still comfortably above my 40% minimum. The deceleration trend is real: Q1 FY25 45% → Q2 48% → Q3 67% (easy comp) → Q4 46%. The FY26 guide implies 25% — th

*…truncated*

# HNGE — Q4 FY25 Earnings Review (Bear)

> Date: 2026-02-12 (updated from 2026-02-11)
> Persona: Bear (PaulWBryant)
> Corpus: No prior writings on HNGE. Applying framework fresh.
> Sources: Q4 FY25 earnings release, Q4 FY25 Investor Presentation

---

## Prior Beliefs (Going Into Q4 FY25)

I would have expected:
- Revenue around $160-165M, given Q3's $154.2M and the sequential cadence
- Continued 50%+ YoY growth, but starting to decelerate given the law of large numbers
- Gross margins holding ~82%
- Progress toward Non-GAAP profitability, maybe breakeven-ish
- Client adds in the 200+ range
- Billings growth at least matching revenue growth

## Updated Beliefs (What Actually Happened)

| Metric | My Expectation | Actual | Verdict |
|--------|---------------|--------|---------|
| Revenue | ~$160-165M | $170.7M | Beat meaningfully |
| YoY Growth | ~50% | 45.5% (but 51% FY) | Slight decel, expected |
| QoQ Growth | ~7-8% | 10.7% | Better than expected |
| Non-GAAP EPS | ~$0.35 | $0.49 | Significantly better |
| Non-GAAP Op Margin | ~15% | 28% | Wow |
| FCF | Positive | $61.5M (36% margin) | Outstanding |
| Clients | ~2,700 | 2,830 (+270 net adds) | Strong |
| Members | ~700K | 782,890 (+47% YoY) | Excellent |
| LTM Billings | ~$640M | $671.4M (+44% YoY) | Billings > Revenue growth |
| NRR | Unknown | >110% | Now disclosed — strong |
| Client Retention | Unknown | 97% | Excellent |

**Every single metric exceeded what I would have expected.** That doesn't happen often. And the investor deck filled in the gaps I was worried about.

## The Numbers Table

| Quarter | Revenue | YoY% | QoQ% | Beat | Non-GAAP EPS | Non-GAAP GM | Non-GAAP OpM | Clients | Members |
|---------|---------|------|------|------|-------------|-------------|--------------|---------|---------|
| Q2 FY25 | $139.1M | ~55% | 12.4% | +$13.8M | $0.275 | 83% | 19% | 2,359 | — |
| Q3 FY25 | $154.2M | 53% | 10.9% | +$12.1M | $0.322 | 83% | 20% | 2,560 | — |
| Q4 FY25 | $170.7M | 46% | 10.7% | +$13.9M | $0.490 

*…truncated*

# HNGE — Q4 FY25 Earnings Review (Saul)

> Date: 2026-02-22
> Quarter: Q4 FY25 (Dec-25)
> Thesis: First earnings review — establishing baseline

## Verdict

Hinge Health is one of those companies where I have to step back and say — these results are just extraordinary. Revenue up 46% in Q4, 51% for the full year, with 85% gross margins and 28% non-GAAP operating margins. That Rule of 40 score is 82. The EPS beat consensus by 250%! And they have a 97% client retention rate plus NDR above 110%. I have been around a long time and I know what exceptional looks like. This qualifies.

**Position: Initiating coverage. Thesis Intact. Strong Hold / Add on pullbacks.**

---

## The Revenue Story

Here is the revenue trajectory — I follow the money, the results:

| | Q124 | Q224 | Q324 | Q424 | Q125 | Q225 | Q325 | Q425 |
| | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|---|---|---|---|---|---|---|---|---|
| Revenue ($m) | 82.7 | 89.8 | 100.6 | 117.3 | 123.8 | 139.1 | 154.2 | 170.7 |
| YoY % | 37.8% | 28.7% | 23.6% | 43.9% | 49.7% | 54.9% | 53.3% | **45.5%** |
| QoQ % | 1.5% | 8.6% | 12.0% | 16.6% | 5.5% | 12.4% | 10.9% | 10.7% |
| GM % [Non-GAAP] | 71% | 77% | 79% | 82% | 81% | 83% | 83% | 85% |
| OpM % [Non-GAAP] | -16% | -4% | -4% | 18% | 12% | 19% | 20% | **28%** |
| FCF ($m) | — | — | 25.0 | 37.3 | 23.0 | 14.0 | 81.0 | 61.5 |
| FCF Margin | — | — | 24.9% | 31.8% | 18.6% | 10.1% | 52.5% | **36.0%** |

Now, the deceleration from 55% to 45% in Q4 is something I need to address honestly. Saul's first principle is revenue growth — accelerating is good, decelerating is a warning. But here the context matters enormously. First, this was Q4, which tends to be the big enterprise signing quarter. Second, FY full-year growth was 51% — that is incredible for a company doing $588 million in revenue. Third — and this is the part that tells me the guide is sandbagged — TTM calculated billings grew 44% to $671 million against TTM revenue of $588 million. Billi

*…truncated*

# HNGE — Hinge Health | Earnings Review Q4 FY25 (Dec-25)

**Date:** 2026-02-22
**Quarter:** Q4 FY25 (ending December 2025)
**Task:** Earnings Review
**Market Cap:** ~$3.3B | **EV/TTM Rev:** 5.6x

---

## The Headline

Oh man. Where to start with a company I'm coming to fresh with zero prior notes.

Q4 FY25 was Hinge Health's third quarter as a public company (IPO'd May 2025 at $32/share), and they absolutely throttled expectations. $170.7M revenue vs. $157M consensus — an 8.7% beat. Non-GAAP EPS of $0.49 vs. $0.14 expected. That's a 250% EPS beat. In their third public quarter.

I keep saying the "Is" vs "Could Be" framework is the most important question I ask about any company. Hinge Health is very clearly an "Is" company. They're not asking me to imagine a future. They're showing me one.

---

## Q4 FY25 Results

| Metric | Q4 FY25 | Q4 FY24 | YoY | Beat? |
|--------|---------|---------|-----|-------|
| Revenue [Non-GAAP] | $170.7M | $117.0M | +46% | +8.7% vs consensus |
| Gross Margin [Non-GAAP] | 85% | 77% | +8pp | — |
| Operating Margin [Non-GAAP] | 28% | — | — | — |
| FCF | $61.5M | — | — | 36% margin |
| EPS [Non-GAAP] | $0.49 | — | — | +250% vs $0.14 consensus |
| Rule of 40 | 81 | — | — | — |

**FY25 Full Year:** $587.9M revenue (+51% YoY), $117M operating income (20% margin), $179.6M FCF.

---

## Key KPIs

| Metric | Q4 FY25 | Q4 FY24 | Commentary |
|--------|---------|---------|-----------|
| Clients | 2,830 | 2,256 | +25% YoY |
| Members | 783K | 532K | +47% YoY |
| Contracted Lives | 24.6M | 20.0M | +23% YoY |
| Client Retention | 97% | 97% | Stable and elite |
| Partner Retention | 100% | 100% | Perfect |
| NDR | 110%+ | 110%+ | Floor, not ceiling |
| TTM Billings | $671.4M | $467.5M | +44% YoY |
| Non-ASO Lives | 2.6M | ~1.1M | +130% YoY |
| Annual Yield | 390% | 340% | Expanding |

The billings-to-revenue ratio is 1.14x — meaning future revenue is already contracted and not yet recognized. That's a bullish leading indicator.

---

## The "Is" vs "C

*…truncated*

# HNGE — Q4 FY25 Earnings Review (muji)

> Date: 2026-02-22
> Quarter: Q4 FY25 (Dec-25)
> Prior analyses: None — establishing first baseline
> Atlas baseline: 4/5 conviction, undervalued at 5.6x TTM rev

---

## Links

- Transcript: [Motley Fool Q4 FY25](https://www.fool.com/earnings/call-transcripts/2026/02/10/hinge-health-hnge-q4-2025-earnings-transcript/)
- Press Release: Q4 FY25 earnings release

---

## The Headline

Q4 FY25: $170.7M revenue (+46% YoY), 85% GM [Non-GAAP], 28% OpM [Non-GAAP], $0.49 non-GAAP EPS (vs $0.14 consensus — 250% beat), $61.5M FCF (36% margin). Rule of 40: 82 !!

FY25 full year: $587.9M (+51% YoY). Non-GAAP operating income $117M (from near-zero in FY24). FCF $179.6M. Rule of 40: 81.

**This is an exceptional result.** Not just the beat — the *character* of the beat.

---

## Platform Assessment (muji's layer)

Here's the thing about Hinge Health that most people are missing through the financial lens alone.

**The annual yield metric is the NRR signal.**

Traditional SaaS has NRR. Hinge Health has annual yield: 3.4% → 3.9% YoY (and first-year 2025 cohorts coming in at 3.3% vs historical 1.3-2.5%). This is the utilization rate of contracted eligible lives. Revenue = contracted lives × yield × revenue per member. When yield expands, you get embedded revenue growth inside existing contracts without adding a single new client.

| Metric | FY23 | FY24 | FY25 | YoY |
|--------|------|------|------|-----|
| Avg Eligible Lives (M) | 12.2 | 15.7 | 20.1 | +28% |
| Annual Yield | ~n/a | 3.4% | 3.9% | +50bps |
| Members | 370,526 | 532,326 | 782,890 | +47% |
| Contracted Lives (M) | n/a | 20.0 | 24.6 | +24% |

Eligible lives growing 28% per year, yield expanding, NDR >110% [Non-GAAP]. **This is a compounding platform effect inside existing relationships** — not a new client story.

**Crowdsourced intelligence flywheel:**

782K members → engagement data → Robin AI improving → better outcomes → 21 peer-reviewed studies → clinical credibility → win mo

*…truncated*

# HNGE — Hinge Health: A Deep Dive Stock Analysis

> **Date:** 2026-03-31
> **Analyst:** Bert Hochfeld
> **Type:** Initiation — Stock Analysis
> **Price:** ~$36.78 (March 30, 2026 close)
> **Market Cap:** ~$3.11B | **EV:** ~$2.63B | **Shares:** 84.5M diluted
> **Brief:** briefs/HNGE_stock-analysis_2026-03-27/

---

## Summary

Hinge Health is a digital musculoskeletal care platform that has emerged from its June 2025 IPO with one of the most impressive financial profiles I have seen in a newly public company. The company grew revenue 51% in FY25 to $587.9M, achieved a non-GAAP operating margin of 28% in Q4, and generated $179.6M in free cash flow — a Rule of 40 score of 81, which places it in elite company. I haven't covered Hinge Health in the newsletter previously, but applying my framework, the valuation is extraordinary: at an EV/S of 4.5X on trailing revenue and 3.6X on FY26 guided revenue of $737M, the stock trades at a 35-45% discount to the cohort average for companies growing at 30-50% CAGR. The FY26 revenue guidance of 25% growth is, in my judgment, deliberately undemanding — Q1 guidance alone implies 39% YoY growth, which is mathematically inconsistent with a full-year number of 25% absent a dramatic H2 collapse that no leading indicator supports. I believe actual FY26 growth will be 33-38%. With a PEG ratio below 0.6X on my growth estimate and a P/FCF of 17X, this is a relative bargain. Primary risk is competitive intensification from the Sword Health/Kaia merger and the unproven economics of non-ASO channels. Recommendation: Buy. Suitable for 3-5% position in the high growth portfolio.

---

## Business Overview

Hinge Health operates a digital-first musculoskeletal care platform that serves self-insured employers through a combination of AI-powered software (Robin AI), wearable devices (Enso), and access to licensed physical therapists and clinicians. The company's value proposition to employers is straightforward: MSK conditions are the #1 driver of e

*…truncated*